Clinical Trial Update: Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer harboring …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING